TY - JOUR
T1 - Differential effects of endogenous and synthetic cannabinoids on voltage-dependent calcium fluxes in rabbit T-tubule membranes
T2 - Comparison with fatty acids
AU - Oz, Murat
AU - Tchugunova, Yulia
AU - Dinc, Meral
PY - 2004/10/11
Y1 - 2004/10/11
N2 - The effects of cannabinoid receptor ligands including 2- arachidonoylglycerol, R-methanandamide, Δ 9-THC (Δ 9-tetrahydrocannabinol), WIN 55,212-2 [4,5-dihydro-2-methyl- 4(4-morpholinylmethyl)-1-(1-naphthalenylcarbonyl)-6H-pyrrolo[3,2,1ij] quinolin-6-one], CP 55,940 ([1alpha,2beta-(R)-5alpha]-(-)-5-(1,1-dimethyl)-2-[5- hydroxy-2-(3-hydroxypropyl) cyclohexyl-phenol]) and a series of fatty acids on depolarization-induced Ca 2+ effluxes mediated by voltage-dependent Ca 2+ channels were investigated comparatively in transverse tubule membrane vesicles from rabbit skeletal muscle. Vesicles were loaded with 45Ca 2+ and membrane potentials were generated by establishing potassium gradients across the vesicle using the ionophore valinomycin. Endocannabinoids, 2-arachidonoylglycerol and R-methanandamide (all 10 μM), inhibited depolarization-induced Ca 2+ effluxes and specific binding of [ 3H]PN 200-110 (isradipine) to transverse tubule membranes. On the other hand, synthetic cannabinoids, including CP 55,940, WIN 55,212-2, and Δ 9-THC (all 10 μM), were ineffective. Additional experiments using endocannabinoid metabolites suggested that whereas ethanolamine and glycerol were ineffective, arachidonic acid inhibited Ca 2+ effluxes and specific binding of [ 3H]PN 200-110. Further studies indicated that only those fatty acids containing two or more double bonds were effective in inhibiting depolarization-induced Ca 2+ effluxes and specific binding of [ 3H]PN 200-110. These results indicate that endocannabinoids, but not synthetic cannabinoids, directly inhibit the function of voltage-dependent calcium channels (VDCCs) and modulate the specific binding of calcium channel ligands of the dihydropyridine (DHP) class.
AB - The effects of cannabinoid receptor ligands including 2- arachidonoylglycerol, R-methanandamide, Δ 9-THC (Δ 9-tetrahydrocannabinol), WIN 55,212-2 [4,5-dihydro-2-methyl- 4(4-morpholinylmethyl)-1-(1-naphthalenylcarbonyl)-6H-pyrrolo[3,2,1ij] quinolin-6-one], CP 55,940 ([1alpha,2beta-(R)-5alpha]-(-)-5-(1,1-dimethyl)-2-[5- hydroxy-2-(3-hydroxypropyl) cyclohexyl-phenol]) and a series of fatty acids on depolarization-induced Ca 2+ effluxes mediated by voltage-dependent Ca 2+ channels were investigated comparatively in transverse tubule membrane vesicles from rabbit skeletal muscle. Vesicles were loaded with 45Ca 2+ and membrane potentials were generated by establishing potassium gradients across the vesicle using the ionophore valinomycin. Endocannabinoids, 2-arachidonoylglycerol and R-methanandamide (all 10 μM), inhibited depolarization-induced Ca 2+ effluxes and specific binding of [ 3H]PN 200-110 (isradipine) to transverse tubule membranes. On the other hand, synthetic cannabinoids, including CP 55,940, WIN 55,212-2, and Δ 9-THC (all 10 μM), were ineffective. Additional experiments using endocannabinoid metabolites suggested that whereas ethanolamine and glycerol were ineffective, arachidonic acid inhibited Ca 2+ effluxes and specific binding of [ 3H]PN 200-110. Further studies indicated that only those fatty acids containing two or more double bonds were effective in inhibiting depolarization-induced Ca 2+ effluxes and specific binding of [ 3H]PN 200-110. These results indicate that endocannabinoids, but not synthetic cannabinoids, directly inhibit the function of voltage-dependent calcium channels (VDCCs) and modulate the specific binding of calcium channel ligands of the dihydropyridine (DHP) class.
KW - Calcium channel
KW - Cannabinoid
KW - Endocannabinoid
KW - Fatty acid
KW - Skeletal muscle
UR - http://www.scopus.com/inward/record.url?scp=4744365699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4744365699&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2004.08.052
DO - 10.1016/j.ejphar.2004.08.052
M3 - Article
C2 - 15464089
AN - SCOPUS:4744365699
SN - 0014-2999
VL - 502
SP - 47
EP - 58
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-2
ER -